Professional
Added to YB: 2024-08-07
Pitch date: 2024-06-30
SAGE [bullish]
Sage Therapeutics, Inc.
-20.07%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
Market Cap
$543.6M
Pitch Price
$10.86
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.64
P/E
-1.78
EV/Sales
2.69
Sector
Biotechnology
Category
growth
Show full summary:
Polen International Growth Portfolio Holding: Sage Therapeutics, Inc.
SAGE: SMB accounting software provider. Stock down on lowered 2H revenue forecast due to macro headwinds. Mission-critical product for SMBs. Mid-teens earnings growth expected despite challenges. Modest margin expansion anticipated. Core value proposition remains strong.
Read full article (1 min)